• 1
    Waimann CA, Marengo MF, de Achaval S, Cox VL, Garcia-Gonzalez A, Reveille JD, et al.Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence.Arthritis Rheum2013;65:14219.
  • 2
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.Arthritis Rheum2006;54:328490.
  • 3
    Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al.Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).Ann Rheum Dis2013;72:178692.
  • 4
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al.Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment in systemic lupus erythematosus.Ann Rheum Dis2007;66:8214.
  • 5
    Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al.Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus.J Rheumatol2012;39:1749.